Patients with seizure disorder may be enrolled if on non-enzyme inducing anticonvulsants and well controlled
Patients must not have received enzyme-inducing anticonvulsants for at least 7 days prior to enrollment
Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled
Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled
Patients with seizure disorder may be enrolled if on non-enzyme inducing anticonvulsants and well controlled
Patients must not have received enzyme inducing anticonvulsants for at least 14 days prior to enrollment
Patients with seizure disorder may be enrolled if on non-enzyme inducing anti-convulsants and well controlled
Patients must not have received enzyme-inducing anticonvulsants for at least 7 days prior to enrollment
Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled; however, drugs that induce CYP3A4/5 (carbamazepine, oxcarbazepine, phenytoin, primidone, phenobarbital) should be avoided
Central nervous system function defined as:\r\n* Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled\r\n* Patients must not be in status epilepticus, a coma or on assisted ventilation at the time of study enrollment
Patients with a known seizure disorder who are receiving non-enzyme inducing anticonvulsants and have well-controlled seizures may be enrolled
Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled
Concomitant use of any enzyme inducing anticonvulsants is not allowed
Subjects who are currently receiving enzyme inducing anticonvulsants are not eligible
Patients with seizure disorder may be enrolled if on non-enzyme inducing anticonvulsants and well controlled
Patients must not currently be receiving enzyme inducing anticonvulsants
Patients receiving concomitant medication that may interfere with study outcome; for example, patients cannot be on enzyme inducing anticonvulsants like phenytoin
Patients receiving treatment with any enzyme-inducing anticonvulsant that cannot be discontinued at least 1 week before first dose of INC280, and for the duration of the study; patients on non-enzyme-inducing anticonvulsants are eligible
Patients with seizure disorder may be enrolled if receiving non-enzyme inducing anticonvulsants and well controlled
Patients with seizure disorder may be enrolled if on non-enzyme inducing anticonvulsants and well controlled.
Patients with known seizure disorder must have seizures adequately controlled with non- enzyme inducing antiepileptic medications
Patients with seizure disorder may be enrolled if on non-enzyme inducing anticonvulsants and well controlled
Patients with seizure disorder may be enrolled if receiving non-enzyme inducing anticonvulsants and well controlled
Patients with seizure disorder may be enrolled if on non-enzyme inducing anticonvulsants and well controlled
Patients who are currently receiving enzyme inducing anticonvulsants are not eligible
Patients with seizure disorder may be enrolled if on non-enzyme inducing anticonvulsants and well controlled
Anticonvulsants: patients on enzyme inducing anticonvulsants (EIAED) will be excluded; if patients were previously on EIAEDs that have been discontinued, patients must have been off EIAEDs for >= 2 weeks prior to initiation of dasatinib
Patients with a seizure disorder may be enrolled if well-controlled and on non-enzyme inducing anticonvulsants
Patients with seizure disorder may be enrolled if well controlled; patients receiving enzyme-inducing anticonvulsants are not eligible for this study; patients must be off enzyme inducing anticonvulsant drugs (EIACD) for at least 2 weeks prior to registration
Patients on enzyme inducing anticonvulsants
Concomitant use of any enzyme inducing anticonvulsants is not allowed
Subjects with seizure disorder may be enrolled if on anticonvulsants and well controlled
Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled
Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled
Treatment with non-enzyme inducing anti-seizure medications is allowed
Central nervous system function defined as:\r\n* Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled\r\n* Patients must not be in status, coma or assisted ventilation prior to study enrollment
Brain metastases that are symptomatic or requiring corticosteroids (except inhaled); subjects must also be off of enzyme-inducing anticonvulsants for > 4 weeks
Central nervous system function defined as\r\n* Patients with a seizure disorder may be enrolled if well-controlled and on non-enzyme inducing anticonvulsants
Patients must not have received enzyme-inducing anticonvulsants including phenytoin, phenobarbital, valproic acid, or carbamazepine for at least 7 days prior to study enrollment; patients receiving non-enzyme inducing anticonvulsants such as gabapentin or levetiracetam will be eligible
Patients with seizure disorder may be enrolled if on non-enzyme inducing anticonvulsants and if seizures are well controlled
Patients who are currently receiving enzyme inducing anticonvulsants are not eligible
Patients with known seizure disorder must have seizures adequately controlled with non-enzyme inducing antiepileptic medications
Participants who are currently receiving enzyme-inducing anticonvulsants
Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled
Patients taking enzyme inducing anticonvulsants
Use of enzyme-inducing anticonvulsants (EIACs); a minimum interval of 10 days between the last dose of EIAC and start of this therapy will be required for research participants who were previously receiving such medications
Central nervous system function defined as:\r\n* Patients with seizure disorder may be enrolled if on non-enzyme inducing anticonvulsants and if seizures are well controlled\r\n* Nervous system disorders (Common Terminology Criteria for Adverse Events [CTCAE] version 4 [v4]) resulting from prior therapy must be =< grade 2
Patients who are currently receiving enzyme inducing anticonvulsants are not eligible
No enzyme inducing anticonvulsants for >= 4 weeks prior to randomization
Patients can only be on non-enzyme inducing anti-convulsants; if they are on an enzyme inducing anti-convulsant, they may be converted to a non-enzyme inducing anticonvulsants
Central Nervous System: Patients without seizure disorder OR patients with well-controlled seizure disorder receiving anticonvulsants may be enrolled on this protocol; anticonvulsants must not be enzyme-inducing (inducers of CYP3A, i.e., no barbiturates, phenytoin, carbamazepine, etc.)
Patients with seizure disorder may be enrolled if on anticonvulsants and well-controlled; central nervous system (CNS) toxicity < grade 2
Patients must not have received enzyme inducing anticonvulsants for at least 14 days prior to enrollment
Patients with a seizure disorder are eligible if well-controlled on anticonvulsants; if on a non-enzyme inducing anticonvulsant, the irinotecan (irinotecan hydrochloride) dose will be adjusted as outline in treatment plan
Patients with brain metastases are eligible provided they meet all other eligibility criteria and do not require corticosteroids or enzyme-inducing anticonvulsants and provided it is felt clinically that they will not require radiotherapy in the three (3) weeks subsequent to their participation in the study
